Discovery of Vanoxerine Dihydrochloride As a CDK2/4/6 Triple-Inhibitor for the Treatment of Human Hepatocellular Carcinoma
Therd Affiliated Hospital of Kunming Medical University,Ke Kun-Bin,Xia Zhong-Kun,Li Hong-Jian,Su Rong,Dong Chao,Zhou Feng-Mei,Wang Lin,Chen Rong,Wu Shi-Guo,Zhao Hui,Gu Peng,Leung Kwong-Sak,Wong Man-Hon,Lu Gang,Zhang Jian-Ying,Jiang Bing-Hua,Qiu Jian-Ge,Southwest Guizhou Vocational and Technical College for Nationalities,Lin Marie Chia-mi
DOI: https://doi.org/10.1186/s10020-021-00269-4
2021-01-01
Molecular Medicine
Abstract:Background: Cyclin-dependent kinases 2/4/6 (CDK2/4/6) play critical roles in cell cycle progression, and their deregulations are hallmarks of hepatocellular carcinoma (HCC). Methods: We used the combination of computational and experimental approaches to discover a CDK2/4/6 triple-inhibitor from FDA approved small-molecule drugs for the treatment of HCC. Results: We identified vanoxerine dihydrochloride as a new CDK2/4/6 inhibitor, and a strong cytotoxic drug in human HCC QGY7703 and Huh7 cells (IC50: 3.79 μM for QGY7703 and 4.04 μM for Huh7 cells). In QGY7703 and Huh7 cells, vanoxerine dihydrochloride treatment caused G1‑arrest, induced apoptosis, and reduced the expressions of CDK2/4/6, cyclin D/E, retinoblastoma protein (Rb), as well as the phosphorylation of CDK2/4/6 and Rb. Drug combination study indicated that vanoxerine dihydrochloride and 5-Fu produced synergistic cytotoxicity in vitro in Huh7 cells. Finally, in vivo study in BALB/C nude mice subcutaneously xenografted with Huh7 cells, vanoxerine dihydrochloride (40mg/kg, i.p.) injection for 21 days produced significant anti‑tumor activity (p<0.05), which was comparable to that achieved by 5-Fu (10mg/kg, i.p.), with the combination treatment resulted in synergistic effect. Immunohistochemistry staining of the tumor tissues also revealed significantly reduced expressions of Rb and CDK2/4/6 in vanoxerine dihydrochloride treatment group. Conclusions: The present study is the first report identifying a new CDK2/4/6 triple inhibitor vanoxerine dihydrochloride, and demonstrated that this drug represents a novel therapeutic strategy for HCC treatment.